0001493152-21-018109.txt : 20210729 0001493152-21-018109.hdr.sgml : 20210729 20210729171243 ACCESSION NUMBER: 0001493152-21-018109 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210723 ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210729 DATE AS OF CHANGE: 20210729 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Intec Pharma Ltd. CENTRAL INDEX KEY: 0001638381 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37521 FILM NUMBER: 211128529 BUSINESS ADDRESS: STREET 1: 12 HARTOM STREET STREET 2: HAR HOTZVIM CITY: JERUSALEM STATE: L3 ZIP: 777512 BUSINESS PHONE: 97225864657 MAIL ADDRESS: STREET 1: 12 HARTOM STREET STREET 2: HAR HOTZVIM CITY: JERUSALEM STATE: L3 ZIP: 777512 8-K 1 form8-k.htm
0001638381 false --12-31 0001638381 2021-07-23 2021-07-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)

July 23, 2021

 

INTEC PHARMA LTD.

(Exact name of registrant as specified in its charter)

 

Israel   001-37521   N/A

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

12 Hartom St.

Har Hotzvim

    
Jerusalem, Israel   9777512
(Address of principal executive offices)   (Zip Code)

 

+ 972-2-586-4657

(Registrant’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☒ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Ordinary Shares, no par value   N/A   N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 2.01 Completion of Acquisition or Disposition of Assets.

 

On July 27, 2021, Intec Pharma Ltd., an Israeli company (the “Company” or “Intec Israel”), Intec Parent, Inc., a Delaware corporation (“Intec Parent”), and Domestication Merger Sub Ltd., an Israeli company and a wholly-owned subsidiary of Intec Parent (the “Domestication Merger Sub”), completed the previously announced domestication merger pursuant to the terms and conditions of the Agreement and Plan of Merger and Reorganization, dated April 27, 2021 (the “Domestication Merger Agreement”), whereby Domestication Merger Sub merged with and into Intec Israel, with Intec Israel being the surviving entity and a wholly-owned subsidiary of Intec Parent (the “Domestication Merger”). As a result of the Domestication Merger, Intec Israel continues to possess all of its assets, rights, powers and property as constituted immediately prior to the Domestication Merger and continues to be subject to all of its debts, liabilities and obligations as constituted immediately prior to the Domestication Merger. The Domestication Merger Agreement was entered into in connection with an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), dated March 15, 2021, by and among Intec Israel, Intec Parent, Domestication Merger Sub, Dillon Merger Subsidiary, Inc. (“Merger Sub”) and Decoy Biosystems, Inc., a Delaware corporation (“Decoy”), whereby upon satisfaction of certain closing conditions set forth in the Merger Agreement, including consummation of the Domestication Merger, the Merger Sub will merge with and into Decoy, with Decoy being the surviving entity and a wholly-owned subsidiary of Intec Parent (the “Merger”).

 

To effect the Domestication Merger, Intec Israel ordinary shares, having no par value per share (the “Intec Israel Shares”), outstanding immediately prior to the Domestication Merger converted, on a one-for-one basis, into shares of Intec Parent common stock, $0.01 par value per share (“Intec Parent Common Stock”), and all options and warrants to purchase Intec Israel Shares outstanding immediately prior to the Domestication Merger were exchanged for equivalent securities of Intec Parent.

 

Consummation of the Domestication Merger was subject to certain closing conditions, including, among other things, the receipt of tax rulings from the Israel Tax Authority (“ITA”). On July 19, 2021, Intec Israel obtained a tax ruling from the ITA approving that the exchange of shares under the Domestication Merger by the Interested Public (as defined herein), in consideration for Intec Parent’s shares shall not constitute a tax event (in accordance with and subject to conditions of Section 104H of the Israeli Income Tax Ordinance [New Version], 5721-1961 (“the Ordinance”)) and therefore no withholding tax obligations apply to Intec Israel with respect to the exchange of shares (the “Tax Ruling”) subject to certain conditions set forth in the Tax Ruling. For the purpose of the Tax Ruling, a shareholder of Intec Israel falls within the definition of the “Interested Public” if, among other things, the shareholder holds less than 5% of the share capital of Intec Israel (on a fully diluted basis), purchased the shares after they were listed for trading, is not an Interested Party under the Israeli Securities Law, 5728-1968, and is not a controlling shareholder as defined in section 103 of the Ordinance. The registration statement on Form S-4, as amended (File No. 333-255389), filed by Intec Israel and Intec Parent as co-registrants with the Securities and Exchange Commission on May 12, 2021 (the “Registration Statement”), contains additional information about the tax consequences of the Domestication Merger.

 

The foregoing description of the Domestication Merger Agreement and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by reference to the Domestication Merger Agreement, which was filed as Exhibit 2.1 to Intec Israel’s Current Report on Form 8-K filed on April 30, 2021.

 

Item 3.01Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

The information set forth in Item 2.01 above and Items 3.03, 5.01 and 5.03 below of this Current Report on Form 8-K is incorporated herein by reference.

 

In connection with the Domestication Merger, on July 26, 2021, Intec Israel requested that Nasdaq effect the Domestication Merger to take effect prior to open of trading on July 27, 2021. At the market open on July 27, 2021, Intec Parent Common Stock commenced trading on the Nasdaq Capital Market under the symbol “NTEC”.

 

Item 3.03 Material Modification to Rights of Security Holders.

 

The information set forth in Item 2.01 and 3.01 above and Item 5.03 below of this Current Report on Form 8-K is incorporated herein by reference.

 

In connection with the Domestication Merger, each Intec Israel Share outstanding immediately prior to the effective time of such merger was converted into one share of Intec Parent Common Stock. At the effective time of the Domestication Merger, each of Intec Israel’s shareholders ceased to have any rights as shareholders of Intec Israel.

 

The rights of the former Intec Israel shareholders who became Intec Parent stockholders will be governed by the Amended and Restated Certificate of Incorporation of Intec Parent (the “Amended and Restated Certificate of Incorporation”), the Amended and Restated Bylaws of Intec Parent (the “Amended and Restated Bylaws”) and the Delaware General Corporation Law. The Registration Statement contains additional information about the Amended and Restated Certificate of Incorporation, the Amended and Restated Bylaws, and the Delaware General Corporation Law, as well as a comparison of rights of the former Intec Israel shareholders with the rights of the Intec Parent stockholders, which are incorporated by reference into this Item 3.03.

 

2
 

 

The foregoing description of the Amended and Restated Certificate of Incorporation and the Amended and Restated Bylaws is qualified in its entirety by reference to the full text of the Amended and Restated Certificate of Incorporation and the Amended and Restated Bylaws which are attached hereto as Exhibit 3.1 and 3.2, respectively, and are incorporated by reference herein.

 

Item 5.03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

The information set forth in Items 2.01, 3.01 and 3.03 above of this Current Report on Form 8-K is incorporated herein by reference.

 

As previously disclosed, on June 21, 2021, Intec Israel held a special meeting of shareholders (the “Special Meeting”). At the Special Meeting, the shareholders approved, among other things, a proposal to grant discretionary authority to Intec Israel’s board of directors (the “Board”), to approve amendments to Intec Israel’s articles of association to effect a reverse share split of the Intec Israel Shares at a ratio within the range from 1-for-2 to 1-for-4, to be effective at the ratio and on a date to be determined by the Board in its sole discretion.

 

The Board subsequently approved a 1-for-4 reverse share split of the Intec Israel Shares (the “Reverse Share Split”), and the Reverse Share Split became effective after the close of trading on July 26, 2021 and prior to the effectiveness of the Domestication Merger.

 

When the Reverse Share Split became effective, every four of the Intec Israel Shares automatically combined into one Intec Israel Share. In addition, proportionate adjustments were made to the exercise prices of Intec Israel’s outstanding options and warrants and to the number of shares issuable under Intec Israel’s existing option plans. Any fraction of an ordinary share that would otherwise have resulted from the Reverse Share Split was be rounded up to the next whole number.

 

As discussed above, in connection with the Domestication Merger, each Intec Israel Share outstanding after the Reverse Share Split and immediately prior to the effective time of the Domestication Merger was converted into one share of Intec Parent Common Stock. The shares of Intec Parent Common Stock outstanding immediately after the effective time of the Domestication Merger commenced trading on the Nasdaq Capital Market at market open on July 27, 2021 under the symbol “NTEC.” The CUSIP number for the shares of Intec Parent Common Stock following the Reverse Share Split and the Domestication Merger is 45828B 100.

 

VStock Transfer, LLC, Intec Israel’s transfer agent, acted as the exchange agent for the Reverse Share Split.

 

For more information about the Reverse Share Split, see the Registration Statement, the relevant portions of which are incorporated herein by reference.

 

Item 8.01 Other Events.

 

On July 23, 2021, Intec Parent entered into a securities purchase agreement (the “Purchase Agreement”) with a certain institutional investor (the “Purchaser”), pursuant to which Intec Parent agreed to sell and issue, in a private placement (the “Private Placement”) a pre-funded warrant to purchase up to 2,727,273 shares of Intec Parent’s common stock (the “Pre-funded Warrant”) and a warrant to purchase up to 2,727,273 of Intec Parent’s common stock (the “Warrant” and together with the “Pre-funded Warrant” and the shares of common stock underlying the Warrant and Pre-funded Warrant, the “Securities”), at a purchase price of $10.99 per Pre-funded Warrant and associated Warrant, for aggregate gross proceeds to Intec Parent of approximately $29.9 million (or approximately $30.0 million assuming the full exercise of the Pre-funded Warrant), before deducting the placement agent’s fees and other estimated offering expenses payable by Intec Parent. The Private Placement is expected to close immediately prior to the closing of the Merger on or about August 3, 2021, subject to satisfaction of customary closing conditions, and is more fully described in the Current Report on Form 8-K filed by Intec Parent on July 29, 2021.

 

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation to buy nor shall there be any sale of the Securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

The Securities are being offered and sold pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506 of Regulation D promulgated thereunder (“Regulation D”). The Purchaser has represented that it is an accredited investor, as defined in Rule 501(a) of Regulation D, or a qualified institutional buyer, as defined in Rule 144A under the Securities Act, and has acquired the Securities as principal for its own account and has no arrangements or understandings for any distribution thereof. The offer and sale of the Securities is being made without any form of general solicitation or advertising. The Securities have not been registered under the Securities Act or applicable state securities laws. Accordingly, the Securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and any applicable state securities laws.

 

On July 26, 2021, Intec Israel issued a press release regarding the Domestication Merger, the Reverse Share Split and the Private Placement. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

3
 

 

Item 9.01 Financial Statement and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
     
2.1   Agreement and Plan of Merger and Reorganization, dated as of April 27, 2021, by and among Intec Pharma Ltd., Intec Parent, Inc. and Domestication Merger Sub Ltd. (incorporated herein by reference to Exhibit 2.1 of the Company’s Form 8-K filed with the SEC on April 30, 2021).
3.1   Amended and Restated Certificate of Incorporation of Intec Parent, Inc., dated as of July 23, 2021 (incorporated herein by reference to Exhibit 3.1 of the Intec Parent, Inc. Form 8-K filed with the SEC on July 23, 2021).
3.2   Amended and Restated Bylaws of Intec Parent, Inc., dated as of July 23, 2021 (incorporated herein by reference to Exhibit 3.2 of the Intec Parent, Inc. Form 8-K filed with the SEC on July 23, 2021).
99.1   Press Release of Intec Pharma Ltd., dated as of July 26, 2021.

 

4
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 29, 2021

 

  INTEC PHARMA LTD.
   
  By: /s/ Nir Sassi
    Nir Sassi
    Chief Financial Officer

 

5

 

 EX-99.1 2 ex99-1.htm

 

 

 

Intec Announces $30 Million Private Placement Ahead of Decoy Merger

 

July 26, 2021 at 8:00 AM EDT

 

- Private placement to be preceded by reverse share split and domestication merger

- Intec Israel to effect 1-for-4 reverse share split after market close on July 26, 2021

- Domestication merger to enter into effect prior to market open on July 27, 2021

- Holders of Intec Israel ordinary shares will become holders of Intec US shares of common stock

- At market open on July 27, 2021, Intec US will begin trading on the Nasdaq Capital Market instead of Intec Israel under Intec Israel’s existing symbol “NTEC”

 

JERUSALEM, July 26, 2021 /PRNewswire/ — Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec Israel” or the “Company”), today announced that its wholly-owned subsidiary, Intec Parent, Inc. (“Intec US”), entered into a securities purchase agreement with a single, healthcare-focused institutional investor to raise $30 million in a private placement. The private placement is being consummated to satisfy one of the closing conditions of the previously announced reverse merger with Decoy Biosystems, Inc. (the “Decoy Merger”).

 

In connection with the Decoy Merger, Intec Israel plans to effect a 1-for-4 reverse share split of its outstanding ordinary shares for the purpose of meeting Nasdaq’s initial listing requirements. Upon effectiveness of the reverse share split, every four shares of Intec Israel’s outstanding ordinary shares will be combined into one ordinary share. In addition, proportionate adjustments will be made to the exercise prices and number of underlying shares of Intec Israel’s outstanding options and warrants and to the number of shares issuable under Intec Israel’s existing option plans.

 

Following completion of the reverse share split, Intec Israel plans to effect a domestication merger whereby Domestication Merger Sub Ltd. (“Domestication Merger Sub”), an Israeli company and a wholly-owned subsidiary of Intec US, will merge with and into Intec Israel with Intec Israel being the surviving entity and a wholly-owned subsidiary of Intec US (the “Domestication Merger”). In connection with the Domestication Merger, all of Intec Israel’s ordinary shares outstanding immediately prior to the Domestication Merger will convert, on a one-for-one basis, into shares of common stock of Intec US, par value $0.01 per share, and all options and warrants to purchase Intec Israel’s ordinary shares outstanding immediately prior to the Domestication Merger will be exchanged for equivalent securities of Intec US. Intec Israel will continue to possess all of its assets, rights, powers and property as constituted immediately prior to the Domestication Merger and it will continue to be subject to all of its debts, liabilities and obligations as constituted immediately prior to the Domestication Merger.

 

Both the reverse share split and Domestication Merger will take place prior to completion of the private placement and Decoy Merger. The reverse share split is scheduled to become effective after trading closes on July 26, 2021 and the Domestication Merger is scheduled to enter into effect prior to market open on July 27, 2021. Following the reverse share split and Domestication Merger, Intec US will begin trading on the Nasdaq Capital Market instead of Intec Israel at the commencement of trading on July 27, 2021 under Intec Israel’s existing symbol “NTEC” but with a new CUSIP number (45828B 100).

 

Pursuant to the securities purchase agreement entered into by and between Intec US and the investor, Intec US will issue 10,909,091 (or 2,727,273 on a post-split basis) shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 10,909,091 (or 2,727,273 on a post-split basis) shares of its common stock, at an effective purchase price of $2.75 (or $11.00 on a post-split basis) per share and associated warrant. The warrants will have a term of five and one-half years, be exercisable immediately following the issuance date and have an exercise price of $2.75 (or $11.00 on a post-split basis) per share.

 

H.C. Wainwright & Co. is acting as the exclusive placement agent for the private placement.

 

Intec US intends to use the net proceeds of the private placement for working capital purposes. The completion of the private placement is a closing condition to the Decoy Merger and the private placement is expected to occur immediately prior to the closing of the Decoy Merger on or about August 3, 2021, subject to satisfaction of customary closing conditions.

 

The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

 

Under a registration rights agreement with the investor, the Company is required to file an initial registration statement with the Securities and Exchange Commission (the “SEC”) covering the resale of the shares of common stock (or common stock equivalents in lieu thereof) to be issued to the investor (including the shares of common stock underlying the warrants) within 30 days and to use best efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event no later than 75 days in the event of a “full review” by the Securities and Exchange Commission.

 

The Domestication Merger and reverse share split will not affect any shareholder’s ownership percentage of Intec Israel’s ordinary shares, except to the extent that the reverse share split would result in any shareholder owning a fractional share. Fractional ordinary shares will be rounded up to the nearest whole share. As a result of the reverse share split, the number of outstanding ordinary shares of Intec Israel will be reduced from approximately 7,370,883 ordinary shares to approximately 1,842,721 ordinary shares.

 

Registered shareholders holding their ordinary shares in book-entry or through a bank, broker or other nominee form do not need to take any action in connection with the reverse share split and Domestication Merger. For those shareholders holding physical share certificates, the Company’s transfer agent, VStock Transfer, LLC, will send instructions for exchanging those certificates for new certificates representing the post-split number of shares. VStock Transfer, LLC can be reached at (212) 828-8436.

 

 
 

 

Additional information about the reverse share split, Domestication Merger and Decoy Merger can be found in the Company’s proxy statement/prospectus included in the registration statement on Form S-4 filed with the Securities and Exchange Commission on May 12, 2021, a copy of which is also available at www.sec.gov or at https://www.intecpharma.com.com/ under the SEC Filings tab located on the Investor Relations page.

 

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state.

 

About Intec Pharma Ltd.

 

Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company’s Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. For more information, visit www.intecpharma.com. Intec Pharma routinely posts information that may be important to investors in the Investor Relations section of its website.

 

Cautionary Note Regarding Forward-Looking Statements

 

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act. These include statements regarding management’s expectations, beliefs and intentions regarding, among other things, our product development efforts, business, financial condition, results of operations, strategies, plans and prospects. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when Intec Israel discusses its plans to effect a reverse share split and Domestication Merger, the expected timing of the reverse share split, Domestication Merger and completion of the private placement and intended use of proceeds. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: risks associated with Intec Pharma’s and Decoy’s ability to consummate the Decoy Merger and the timing of the closing of the Decoy Merger, including the risks that a condition to closing would not be satisfied within the expected timeframe or at all or that the closing of the Decoy Merger will not occur; risks related to the ability to consummate certain closing conditions including the private placement and the disposition of the Accordion Pill business, the occurrence of any event, change, or other circumstances that could give rise to the termination of the merger agreement; the outcome of any legal proceedings that may be instituted against Intec Pharma or Decoy following the announcement of the merger agreement and the transactions contemplated therein; unanticipated difficulties or expenditures relating to the Decoy Merger, the response of business partners and competitors to the announcement of the Decoy Merger, and/or potential difficulties in employee retention as a result of the announcement and pendency of the Decoy Merger; the occurrence of any event, change, or other circumstance that could give rise to the termination of the merger agreement or could otherwise cause the transaction to fail to close; the inability to list the merger shares on Nasdaq or maintain the listing of the combined company’s shares of common stock on Nasdaq following the Decoy Merger; the ability to recognize the anticipated benefits of the Decoy Merger. Risks and uncertainties relating to Decoy that may cause actual results to differ materially from those expressed or implied in any forward-looking statement include, but not limited to: Decoy’s plans to develop and potentially commercialize its technology, the timing and cost of Decoy’s planned investigational new drug application and any clinical trials, the completion and receiving favorable results in any clinical trials, Decoy’s ability to obtain and maintain regulatory approval of any product candidate, Decoy’s ability to protect and maintain its intellectual property and licensing arrangements, Decoy’s ability to develop, manufacture and commercialize its product candidates, the risk of product liability claims, the availability of reimbursement, the influence of extensive and costly government regulation, and Decoy’s estimates regarding future revenue, expenses capital requirements and the need for additional financing following Decoy Merger. These risks, as well as other risks and uncertainties associated with Decoy Merger, are discussed in the proxy statement/prospectus that is included in the registration statement on Form S-4 that was filed with the SEC in connection with the Decoy Merger. Additional risks and uncertainties are identified and discussed under the heading “Risk Factors” in Intec Israel’s Annual Report and other period filings with the SEC. All forward-looking statements speak only as of the date of this presentation and are expressly qualified in their entirety by the cautionary statements included in this presentation. Neither Intec Israel nor Decoy undertake any obligation to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events, except as required by applicable law.

 

Intec Pharma Investor Contact:

 

Will O’Connor

Stern IR

+1 212-362-1200

will@sternir.com

 

 

 GRAPHIC 3 ex99-1_1.jpg begin 644 ex99-1_1.jpg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ntec-20210723.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 ntec-20210723_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 ntec-20210723_pre.xml XBRL PRESENTATION FILE XML 7 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001638381 2021-07-23 2021-07-23 iso4217:USD shares iso4217:USD shares 0001638381 false --12-31 8-K 2021-07-23 INTEC PHARMA LTD. L3 001-37521 12 Hartom St. Har Hotzvim Jerusalem, IL 9777512 972-2 586-4657 true false false false Ordinary Shares, no par value false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Jul. 23, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 23, 2021
Current Fiscal Year End Date --12-31
Entity File Number 001-37521
Entity Registrant Name INTEC PHARMA LTD.
Entity Central Index Key 0001638381
Entity Incorporation, State or Country Code L3
Entity Address, Address Line One 12 Hartom St.
Entity Address, Address Line Two Har Hotzvim
Entity Address, City or Town Jerusalem,
Entity Address, Country IL
Entity Address, Postal Zip Code 9777512
City Area Code 972-2
Local Phone Number 586-4657
Written Communications true
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Ordinary Shares, no par value
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://intecpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm ntec-20210723.xsd ntec-20210723_lab.xml ntec-20210723_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "ntec-20210723_lab.xml" ] }, "presentationLink": { "local": [ "ntec-20210723_pre.xml" ] }, "schema": { "local": [ "ntec-20210723.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "NTEC", "nsuri": "http://intecpharma.com/20210723", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2021-07-23to2021-07-23", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://intecpharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2021-07-23to2021-07-23", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 16 0001493152-21-018109-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-21-018109-xbrl.zip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
&UL4$L%!@ 0 % 4 -@$ !E/ $! end